Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease
Abstract
Growing evidence demonstrates that circulating tumor DNA (ctDNA) minimal residual disease (MRD) following treatment for solid tumors predicts relapse. These results suggest that ctDNA MRD could identify candidates for adjuvant therapy and measure response to such treatment. Importantly, factors such as assay type, amount of ctDNA release, and technical and biological background can affect ctDNA MRD results. Furthermore, the clinical utility of ctDNA MRD for treatment personalization remains to be fully established. Here, we review the evidence supporting the value of ctDNA MRD in solid cancers and highlight key considerations in the application of this potentially transformative biomarker.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Dec 01, 2021
- Source ID
- 10.1158/2159-8290.cd-21-0634
Entities
People
- A Alizadeh
- Barzin Y. Nabet
- Everett J Moding
- Maximilian Diehn
Organizations
- Intelligence Community Postdoctoral Research Fellowship Program
- Leukemia & Lymphoma Society
- National Cancer Institute
- National Institutes of Health
- Stanford University